<DOC>
	<DOCNO>NCT01430611</DOCNO>
	<brief_summary>This study part post-licensure commitment evaluate safety immunogenicity Meningo A+C vaccine healthy Chinese child 2 6 year age . Primary Objective : To demonstrate non-inferiority term seroconversion rate serogroups A C , 30 day single dose Sanofi Pasteur Meningococcal ( Groups A C ) Polysaccharide Vaccine versus Lanzhou Institute Biological Products Meningococcal ( Groups A C ) Polysaccharide Vaccine . Secondary Objective : - To describe immunogenicity serogroups A C , 30 day administration study vaccine give single dose . - To describe full reactogenicity profile administration study vaccine give single dose .</brief_summary>
	<brief_title>Study Sanofi Pasteur Lanzhou Institute 's Meningococcal ( Group A C ) Polysaccharide Vaccine Children</brief_title>
	<detailed_description>Eligible participant receive one injection either Sanofi Pasteur Meningococcal ( Groups A C ) Polysaccharide Vaccine Lanzhou Institute Biological Products Meningococcal ( Groups A C ) Polysaccharide Vaccine monitor safety immunogenicity 30 day post-vaccination .</detailed_description>
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Meningococcal Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 2 6 year day inclusion Informed consent form sign dated parent another legally acceptable representative Subject parent/ legally acceptable representative able attend schedule visit comply trial procedure Written documentation immunization history meningococcal disease accord national Expanded Program Immunization ( EPI ) schedule ( include 2 dos Meningococcal Group A Polysaccharide Vaccine 6 18 month age ) . Participation 4 week precede trial vaccination plan participation present trial period another clinical trial investigate vaccine , drug , medical device , medical procedure Receipt vaccine 4 week precede trial vaccination plan receipt vaccine 4 week follow trial vaccination ( except influenza vaccination , may receive least 2 week study vaccine ) Previous vaccination meningococcal disease within past 12 month either trial vaccine another vaccine Previous vaccination meningococcal conjugate vaccine . Receipt immune globulin , blood bloodderived product past 3 month Known suspected congenital acquire immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy , within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) History meningococcal infection , confirm either clinically , serologically , microbiologically At high risk meningococcal disease trial , include : 1. person increase susceptibility persistent complement component deficiency , 2. person anatomic functional asplenia , 3. person exposure ( e.g. , microbiologist routinely work N. meningitidis , traveler resident area meningococcal disease hyperendemic epidemic ) Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine use trial vaccine contain substance Known thrombocytopenia , report parent/ legally acceptable representative , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Chronic illness , opinion investigator , stage might interfere trial conduct completion Moderate severe acute illness/infection ( accord investigator judgment ) day vaccination febrile illness ( axillary temperature ≥ 37.1°C ) . A prospective subject include study condition resolve febrile event subside Receipt oral inject antibiotic therapy within 72 hour first blood draw Identified natural adopt child Investigator employee direct involvement propose study Any contraindication list study vaccine leaflet .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Meningitis</keyword>
	<keyword>Neisseria meningitidis</keyword>
	<keyword>Meningo A+C®</keyword>
	<keyword>Meng Ling Kang®</keyword>
</DOC>